x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012011
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Rat |
| Applications | WB, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val84 of human FABP7 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | FABP7 |
| UniProt No. | O15540 |
| Gene ID | 2173 |
| Gene Description | Fatty acid binding proteins bind to fatty acids and other lipids to function as cytoplasmic lipid chaperones. They participate in the transport of fatty acids and other lipids to various cellular pathways. Differential expression of FABPs is found in several types of tumors and their normal-cell counterparts. FABP7 is abundantly expressed in fetal brain and may be essential for development. Expression is required for the establishment of the radial glial fiber system, a system that is necessary for the development of cortical layers. Increased expression of FABP7 is associated with reduced survival in patients with glioblastoma, and is also found in glial cells following nerve injury. Investigators have found loss of FABP7 may be involved in the development and progression of breast cancer and expression of FABP7 has been shown to induce mammary differentiation and to inhibit growth of breast cancer cells. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
